Soorya Patra

My first question is on the respiratory portfolio. How big is the respiratory portfolio contribution to the overall business for Lupin right now? In terms of the U.S. business, what would be its share currently?

From the Albuterol side, for which the market share, has to some extent subsided from the level of 19% - 20% to 16% currently, and possibly we have already reached the peak potential of Tiotropium. So here, in the mid -term, till the time that the pipeline products are getting launched in the U.S., is it fair to believe that the respiratory portfolio in the U.S.

My next question is on the Europe business, which has been doing great for us, and that is visible even in this quarter. But I was just going through the kind of a higher rebate policy initiated by Germany, wherein they are kind of doubling the rebate requirement. What would be your reading about either profitability or pricing pressure what we can see in the European market?